Ticker:

NYSE: MRK

Description:

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.

Website:

www.merck.com

Employees:

55,200

2008 Revenues:

$23.9 billion

2008 Revenue by Geographic Region:

United States - $13,371 million
Europe, Middle East and Africa - $5,774 million
Japan - $1,824 million
Other - $2,883 million

2008 R&D Investment:

$4.8 billion

Headquarters:

Whitehouse Station, New Jersey

Cash and investments (as of 12/31/08):

$12 billion

Major pharmaceutical and vaccine products:

Singulair (montelukast sodium)
Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)
Cozaar (losartan potassium) and Hyzaar (losartan potassium and hydrochlorothiazide)
Gardasil (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant)
Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride)

Novel products in late stage development:

CV: MK-0859 (anacetrapib), MK-7418 (rolofylline), MK-524 A and B (extended-release niacin/laropiprant and extended-release niacin/laropiprant/simvastatin)
Oncology: MK-8669 (deforolimus)
Neuroscience: MK-0974 (telcagepant)
Women's Health: MK-0822 (odanacatib) and V-503

Business segments:

Prescription
Vaccine
Animal Health joint venture (Merial)
Consumer Health joint venture (J&J-Merck)

Executive Management Team:

Richard T. Clark, chairman, president and chief executive officer

Willie A. Deese, executive vice president and president, Merck Manufacturing Division

Kenneth C. Frazier, executive vice president and president, Global Human Health

Mirian Graddick-Weir, executive vice president, Human Resources

Peter N. Kellogg, executive vice president and chief financial officer

Peter S. Kim, Ph.D., executive vice president and president, Merck Research Laboratories

Bruce N. Kuhlik, executive vice president and general counsel

J. Chris Scalet, executive vice president, Global Services, and chief information officer